Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric).

Khasraw, M; McCowatt, SA; Kerestes, Z; Buyse, ME; Back, M; Wheeler, H

File(s) not publicly available

Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric).

Version 2 2024-06-13, 14:16

Version 1 2021-01-13, 15:07

conference contribution

posted on 2024-06-13, 14:16 authored by M Khasraw, SA McCowatt, Z Kerestes, ME Buyse, M Back, H Wheeler

Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric).

History

Volume

29

Publisher DOI

https://doi.org/10.1200/jco.2011.29.15_suppl.tps133

ISSN

0732-183X

eISSN

1527-7755

Language

English

Author URL

https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000208880304558&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a045e4b2bb1f2b747c68c720ec8913b7

Publication classification

E3.1 Extract of paper

Title of proceedings

JOURNAL OF CLINICAL ONCOLOGY

Issue

15

Publisher

AMER SOC CLINICAL ONCOLOGY

Usage metrics

Keywords

Science & Technology Life Sciences & Biomedicine Oncology

Licence

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

File(s) not publicly available

Radiotherapy (RT), temozolomide (TMZ), procarbazine (PCB), and the integrin inhibitor cilengitide in patients with glioblastoma (GBM) without methylation of the MGMT gene promoter (ExCentric).

History

Volume

Publisher DOI

ISSN

eISSN

Language

Author URL

Publication classification

Title of proceedings

Issue

Publisher

Usage metrics

Categories

Keywords

Licence

Exports